Advanced search
Publication Cover
Pharmaceutical Biology Volume 55, 2017 - Issue 1
Submit an article Journal homepage
2,001
Views
33
CrossRef citations to date
0
Altmetric
Research Article

The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism

Xianming WangDepartment of General Surgery, Qianfoshan Hospital affiliated to Shandong University, Shandong, China
,
Xin ZhangDepartment of General Surgery, Qianfoshan Hospital affiliated to Shandong University, Shandong, China
,
Fei LiuDepartment of General Surgery, Qianfoshan Hospital affiliated to Shandong University, Shandong, China
,
Minghai WangDepartment of General Surgery, Qianfoshan Hospital affiliated to Shandong University, Shandong, ChinaCorrespondence[email protected]
&
Shiyong QinDepartment of General Surgery, Qianfoshan Hospital affiliated to Shandong University, Shandong, ChinaCorrespondence[email protected]
Pages 1863-1867 | Received 01 Feb 2017, Accepted 07 Jun 2017, Published online: 14 Jun 2017

Reference

  • Abdel-Rahman O. 2013. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside. J Egypt Natl Canc Inst. 25:165–171.
  • Abdulghani J, Allen JE, Dicker DT, Liu YY, Goldenberg D, Smith CD, Humphreys R, El-Deiry WS. 2013. Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. PLoS One. 8:e75414.
  • Ahmadi M, Ahmadihosseini Z, Allison SJ, Begum S, Rockley K, Sadiq M, Chintamaneni S, Lokwani R, Hughes N, Phillips RM. 2014. Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors. Br J Pharmacol. 171:224–236.
  • Alsaied OA, Sangwan V, Banerjee S, Krosch TC, Chugh R, Saluja A, Vickers SM, Jensen EH. 2014. Sorafenib and triptolide as combination therapy for hepatocellular carcinoma. Surgery. 156:270–279.
  • Bhatt VR, Ganti AK. 2014. Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role. Future Oncol. 10:17–20.
  • Booth LA, Tavallai S, Hamed HA, Cruickshanks N, Dent P. 2014. The role of cell signalling in the crosstalk between autophagy and apoptosis. Cell Signal. 26:549–555.
  • Brown WS, Khalili JS, Rodriguez-Cruz TG, Lizee G, McIntyre BW. 2014. B-Raf regulation of integrin alpha-4-beta-1-mediated resistance to shear stress through changes in cell spreading and cytoskeletal association in T cells. J Biol Chem. 289:23141–23153.
  • Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, et al. 2014. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology. 59:1435–1447.
  • Doi N, Tomita M, Hayashi M. 2011. Absorption enhancement effect of acylcarnitines through changes in tight junction protein in Caco-2 cell monolayers. Drug Metab Pharmacokinet. 26:162–170.
  • Gillani TB, Rawling T, Murray M. 2014. Cytochrome P450-mediated biotransformation of sorafenib and its n-oxide metabolite: implications for cell viability and human toxicity. Chem Res Toxicol. 28:92–102.
  • Hornecker M, Blanchet B, Billemont B, Sassi H, Ropert S, Taieb F, Mir O, Abbas H, Harcouet L, Coriat R, et al. 2012. Saturable absorption of sorafenib in patients with solid tumors: a population model. Invest New Drugs. 30:1991–2000.
  • Kim A, Widemann BC, Krailo M, Jayaprakash N, Fox E, Weigel B, Blaney SM. 2015. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer. 62:1562–1566.
  • Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. 2006. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 57:685–692.
  • Li H, Liu L, Xie L, Gan D, Jiang X. 2016. Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. Pharm Biol. 54:2886–2894.
  • Qi XY, Liang SC, Ge GB, Liu Y, Dong PP, Zhang JW, Wang AX, Hou J, Zhu LL, Yang L, et al. 2013. Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes. Food Chem Toxicol. 56:392–397.
  • Schmithals C, Koberle V, Korkusuz H, Pleli T, Kakoschky B, Augusto EA, Ibrahim AA, Arencibia JM, Vafaizadeh V, Groner B, et al. 2015. Improving drug penetrability with iRGD leverages the therapeutic response to sorafenib and doxorubicin in hepatocellular carcinoma. Cancer Res. 75:3147–3154.
  • Shimada M, Okawa H, Kondo Y, Maejima T, Kataoka Y, Hisamichi K, Maekawa M, Matsuura M, Jin Y, Mori M, et al. 2015. Monitoring serum levels of sorafenib and its n-oxide is essential for long-term sorafenib treatment of patients with hepatocellular carcinoma. Tohoku J Exp Med. 237:173–182.
  • Tlemsani C, Huillard O, Arrondeau J, Boudou-Rouquette P, Cessot A, Blanchet B, Thomas-Schoemann A, Coriat R, Durand JP, Giroux J, et al. 2015. Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib. Expert Opin Drug Metab Toxicol. 11:785–794.
  • Wang X, Zhang X, Huang X, Li Y, Wu M, Liu J. 2015. The drug–drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4. Xenobiotica. 18:1–8.
  • Wang XQ, Fan JM, Liu YO, Zhao B, Jia ZR, Zhang Q. 2011. Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat. Int J Pharm. 419:339–346.
  • Zimmerman EI, Roberts JL, Li L, Finkelstein D, Gibson A, Chaudhry AS, Schuetz EG, Rubnitz JE, Inaba H, Baker SD. 2012. Ontogeny and sorafenib metabolism. Clin Cancer Res. 18:5788–5795.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.